1
|
Foley JF. Taking down tumors takes atypical integrins. Sci Signal 2024; 17:eadp7684. [PMID: 38626008 DOI: 10.1126/scisignal.adp7684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2024] [Accepted: 04/10/2024] [Indexed: 04/18/2024]
Abstract
An unexpected integrin pairing enhances T cell receptor signaling and cytotoxicity in antitumor T cells.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
2
|
Foley JF. Polarizing itch. Sci Signal 2024; 17:eadp2197. [PMID: 38502731 DOI: 10.1126/scisignal.adp2197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2024] [Accepted: 03/13/2024] [Indexed: 03/21/2024]
Abstract
An itch-associated GPCR on neutrophils controls their activation during bacterial infection.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
3
|
Foley JF. Poachers turned gamekeepers in T cells. Sci Signal 2024; 17:eado6463. [PMID: 38377178 DOI: 10.1126/scisignal.ado6463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2024] [Accepted: 02/13/2024] [Indexed: 02/22/2024]
Abstract
The efficacy of therapeutic T cells is enhanced by incorporating mutations associated with autoimmunity or lymphoma.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
4
|
Vignieri S, Lavine MS, Yeston JS, Suleymanov Y, Olingy C, Ash C, Matsiko A, Smith HJ, Alderton G, Nusinovich Y, Funk MA, Seale M, Jiang D, Ross SH, Hallberg DL, Aldenderfer M, Foley JF, Shilatifard A. In Science Journals. Science 2024; 383:715-717. [PMID: 38359142 DOI: 10.1126/science.ado6282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2024]
Abstract
Highlights from the Science family of journals.
Collapse
|
5
|
Seale M, Funk MA, Stajic J, Olingy C, Scanlon ST, Smith HJ, Grocholski B, Czajka C, Yeston JS, Alderton G, Ash C, Smith KT, Lopez B, Vignieri S, Jiang D, Foley JF. In Science Journals. Science 2024; 383:379-381. [PMID: 38271519 DOI: 10.1126/science.ado2171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2024]
Abstract
Highlights from the Science family of journals.
Collapse
|
6
|
Foley JF. Systemic inflammation from the brain. Sci Signal 2024; 17:eadn9627. [PMID: 38227685 DOI: 10.1126/scisignal.adn9627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Accepted: 01/09/2024] [Indexed: 01/18/2024]
Abstract
The actions of glucagon-like peptide 1 receptor agonists in the CNS reduce systemic inflammation.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA
| |
Collapse
|
7
|
Jiang D, Yeston JS, Isles HM, Ray LB, Smith HJ, Grocholski B, Stajic J, Foley JF, Simonti C, Funk MA, Vignieri S, Smith KT, Scanlon ST, Malo C. In Science Journals. Science 2023; 382:1009-1011. [PMID: 38033083 DOI: 10.1126/science.adn1878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2023]
Abstract
Highlights from the Science family of journals.
Collapse
|
8
|
Abstract
Ruptures in lysosomal membranes stimulate the formation of stress granules that plug the holes to enable repair.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
9
|
Lopez B, Suleymanov Y, Chiang JCH, Stajic J, Osborne IS, Vignieri S, Ash C, Olingy C, Lempriere SA, Lavine MS, Funk MA, Nusinovich Y, Smith HJ, Seale M, Jiang D, Grocholski B, Smith O, Foley JF. In Science Journals. Science 2023; 382:659-661. [PMID: 37943910 DOI: 10.1126/science.adm7953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2023]
Abstract
Highlights from the Science family of journals.
Collapse
|
10
|
Zhu W, Chen C, Zhang L, Hoyt T, Walker E, Venkatesh S, Zhang F, Qureshi F, Foley JF, Xia Z. Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosis. Brain Commun 2023; 6:fcad300. [PMID: 38192492 PMCID: PMC10773609 DOI: 10.1093/braincomms/fcad300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 09/08/2023] [Accepted: 10/31/2023] [Indexed: 01/10/2024] Open
Abstract
Few studies examined blood biomarkers informative of patient-reported outcome (PRO) of disability in people with multiple sclerosis (MS). We examined the associations between serum multi-protein biomarker profiles and patient-reported MS disability. In this cross-sectional study (2017-2020), adults with diagnosis of MS (or precursors) from two independent clinic-based cohorts were divided into a training and test set. For predictors, we examined seven clinical factors (age at sample collection, sex, race/ethnicity, disease subtype, disease duration, disease-modifying therapy [DMT], and time interval between sample collection and closest PRO assessment) and 19 serum protein biomarkers potentially associated with MS disease activity endpoints identified from prior studies. We trained machine learning (ML) models (Least Absolute Shrinkage and Selection Operator regression [LASSO], Random Forest, Extreme Gradient Boosting, Support Vector Machines, stacking ensemble learning, and stacking classification) for predicting Patient Determined Disease Steps (PDDS) score as the primary endpoint and reported model performance using the held-out test set. The study included 431 participants (mean age 49 years, 81% women, 94% non-Hispanic White). For binary PDDS score, combined feature input of routine clinical factors and the 19 proteins consistently outperformed base models (comprising clinical features alone or clinical features plus one single protein at a time) in predicting severe (PDDS ≥ 4) versus mild/moderate (PDDS < 4) disability across multiple machine learning approaches, with LASSO achieving the best area under the curve (AUCPDDS = 0.91) and other metrics. For ordinal PDDS score, LASSO model comprising combined clinical factors and 19 proteins as feature input (R2PDDS = 0.31) again outperformed base models. The two best-performing LASSO models (i.e., binary and ordinal PDDS score) shared six clinical features (age, sex, race/ethnicity, disease subtype, disease duration, DMT efficacy) and nine proteins (cluster of differentiation 6, CUB-domain-containing protein 1, contactin-2, interleukin-12 subunit-beta, neurofilament light chain [NfL], protogenin, serpin family A member 9, tumor necrosis factor superfamily member 13B, versican). By comparison, LASSO models with clinical features plus one single protein at a time as feature input did not select either NfL or glial fibrillary acidic protein (GFAP) as a final feature. Forcing either NfL or GFAP as a single protein feature into models did not improve performance beyond clinical features alone. Stacking classification model using five functional pathways to represent multiple proteins as meta-features implicated those involved in neuroaxonal integrity as significant contributors to predictive performance. Thus, serum multi-protein biomarker profiles improve the prediction of real-world MS disability status beyond clinical profile alone or clinical profile plus single protein biomarker, reaching clinically actionable performance.
Collapse
Affiliation(s)
- Wen Zhu
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Chenyi Chen
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Lili Zhang
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Tammy Hoyt
- Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, UT, USA
| | - Elizabeth Walker
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Shruthi Venkatesh
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Fujun Zhang
- Octave Bioscience, Inc., Menlo Park, CA, USA
| | | | - John F Foley
- Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, UT, USA
| | - Zongqi Xia
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
| |
Collapse
|
11
|
Osborne IS, Seale M, Foley JF, Stajic J, Funk MA, Hurtley SM, Fogg CN, Malo C, Lempriere SA, Vignieri S, Stern P, Yeston JS, Isles HM. In Science Journals. Science 2023; 382:413-415. [PMID: 37883567 DOI: 10.1126/science.adl5300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2023]
Abstract
Highlights from the Science family of journals.
Collapse
|
12
|
Foley JF. Restraining neuroinflammation in Alzheimer's disease. Sci Signal 2023; 16:eadl4458. [PMID: 37874886 DOI: 10.1126/scisignal.adl4458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2023]
Abstract
CD8+ T cells recruited to the brain in a mouse model of Alzheimer's disease limit disease pathology.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
13
|
Grocholski B, Maroso M, Yeston JS, Ross SH, Lavine MS, Hallberg DL, Funk MA, Vignieri S, Alderton G, Kelly PN, Foley JF. In Science Journals. Science 2023; 382:182-184. [PMID: 37824639 DOI: 10.1126/science.adl2196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2023]
Abstract
Highlights from the Science family of journals.
Collapse
|
14
|
Hodges K, Osborne IS, Neuhofer D, Ash C, Grocholski B, Yeston JS, Foley JF, Alderton G, Lavine MS, Simonti C, Vignieri S, Nusinovich Y, Isles HM. In Science Journals. Science 2023; 381:1423-1425. [PMID: 37769098 DOI: 10.1126/science.adl0395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2023]
Abstract
Highlights from the Science family of journals.
Collapse
|
15
|
Abstract
Switching between tetrameric and pentameric states regulates the pore size of the ion channel TRPV3.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
16
|
Smith KT, Suleymanov Y, Szuromi P, Smith HJ, Maroso M, Olingy C, Malo C, Funk MA, Vignieri S, Scanlon ST, Nusinovich Y, Osborne IS, Jiang D, Lavine MS, Foley JF, Lempriere SA. In Science Journals. Science 2023; 381:743-745. [PMID: 37590337 DOI: 10.1126/science.add3508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/19/2023]
Abstract
Highlights from the Science family of journals.
Collapse
|
17
|
Abstract
SARS-CoV-2 binds to a lysosomal transmembrane protein to enter cells independently of ACE2.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
18
|
Abstract
GINIP promotes Gβγ signaling while inhibiting Gαi signaling to fine-tune GPCR-mediated neuromodulation.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
19
|
Lopez B, Jiang D, Smith KT, Osborne IS, Szuromi P, Ghose R, Norton M, Hurtley SM, Simonti C, Ray LB, Olingy C, Foley JF. In Science Journals. Science 2023; 380:1333-1335. [PMID: 37384678 DOI: 10.1126/science.adj4221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/01/2023]
Abstract
Highlights from the Science family of journals.
Collapse
|
20
|
Abstract
Preassociation of β-arrestins with the plasma membrane facilitates their interactions with GPCRs.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
21
|
Abstract
Stress-induced changes in gut microbiota cause γδ T cell migration to the meninges, where they affect behavior in mice.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
22
|
Malo CS, Kelly PN, Suleymanov Y, Osborne IS, Yeston J, Szuromi P, Grocholski B, Williams I, Alderton G, Funk MA, Scanlon ST, Foley JF, Jiang D. In Science Journals. Science 2023; 380:49-50. [PMID: 37023179 DOI: 10.1126/science.adi1008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/08/2023]
Abstract
Highlights from the Science family of journals.
Collapse
|
23
|
Abstract
Membrane blebs form signaling hubs that enable tumor cells to resist death by anoikis.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
24
|
Lopez B, Stajic J, Foley JF, Smith HJ, Seale M, Grocholski B, Norton M, Jiang D, Simonti C, Vignieri S, Yeston J, Williams I. In Science Journals. Science 2023. [PMID: 36862796 DOI: 10.1126/science.adh3700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
Highlights from the Science family of journals.
Collapse
|
25
|
Foley JF, Campbell N, Kong G. Extended-interval dosing of natalizumab in NOVA - Authors' reply. Lancet Neurol 2023; 22:200-201. [PMID: 36804085 DOI: 10.1016/s1474-4422(23)00034-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Revised: 11/23/2022] [Accepted: 01/17/2023] [Indexed: 02/17/2023]
Affiliation(s)
- John F Foley
- Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, UT 84103, USA.
| | | | | |
Collapse
|
26
|
Abstract
Dopamine reduces the allergen-induced responses of group 2 innate lymphoid cells to alleviate airway inflammation in mice.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
27
|
Ryerson LZ, Foley JF, Defer G, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Sinks S, Kuhelj R, Bodhinathan K, Lasky T. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2023; 72:104561. [PMID: 36931078 DOI: 10.1016/j.msard.2023.104561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 02/09/2023] [Indexed: 02/12/2023]
Abstract
BACKGROUND Natalizumab (TYSABRI®) 300 mg administered intravenously every-4-weeks (Q4W) is approved for treatment of relapsing-remitting multiple sclerosis but is associated with increased risk of progressive multifocal leukoencephalopathy (PML). Extended natalizumab dosing intervals of approximately every-6-weeks (Q6W) are associated with a lower risk of PML. Primary and secondary clinical outcomes from the NOVA randomized clinical trial (NCT03689972) suggest that effective disease control is maintained in patients who were stable during treatment with natalizumab Q4W for ≥12 months and who then switched to Q6W dosing. We compared additional exploratory clinical and patient-reported outcomes (PROs) from NOVA to assess the efficacy of Q6W dosing. METHODS Prespecified exploratory clinical efficacy endpoints in NOVA included change from baseline in Expanded Disability Status Scale (EDSS) score, Timed 25-Foot Walk (T25FW), dominant- and nondominant-hand 9-Hole Peg Test (9HPT), and Symbol Digit Modalities Test (SDMT). Exploratory patient-reported outcome (PRO) efficacy endpoints included change from baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM), Neuro-QoL fatigue questionnaire, Multiple Sclerosis Impact Scale (MSIS-29), EuroQol 5 Dimensions (EQ-5D-5 L) index score, Clinical Global Impression (CGI)-Improvement (patient- and clinician-assessed) and CGI-Severity (clinician-assessed) rating scales. Estimated proportions of patients with confirmed EDSS improvement were based on Kaplan-Meier methods. Estimates of mean treatment differences for Q6W versus Q4W in other outcomes were assessed by least squares mean (LSM) and analyzed using a linear mixed model of repeated measures or ordinal logistic regression (CGI-scale). RESULTS Exploratory clinical and patient-reported outcomes were assessed in patients who received ≥1 dose of randomly assigned study treatment and had ≥1 postbaseline efficacy assessment (Q6W group, n = 247, and Q4W group, n = 242). Estimated proportions of patients with EDSS improvement at week 72 were similar for Q6W and Q4W groups (11.7% [19/163] vs 10.8% [17/158]; HR 1.02 [95% confidence interval [CI], 0.53-1.98]; P = 0.9501). At week 72, there were no significant differences between Q6W and Q4W groups in LSM change from baseline for T25FW (0.00, P = 0.975), 9HPT (dominant [0.22, P = 0.533] or nondominant [0.09, P = 0.862] hand), or SDMT (-1.03, P = 0.194). Similarly, there were no significant differences between Q6W and Q4W groups in LSM change from baseline for any PRO (TSQM, -1.00, P = 0.410; Neuro-QoL fatigue, 0.52, P = 0.292; MSIS-29 Psychological, 0.67, P = 0.572; MSIS-29 Physical, 0.74, P = 0.429; EQ-5D-5 L, 0.00, P = 0.978). For the EQ-5D-5 L, a higher proportion of Q6W patients than Q4W patients demonstrated worsening (≥0.5 standard deviation increase in the EQ-5D-5 L index score; P = 0.0475). From baseline to week 72 for Q6W versus Q4W, odds ratio (ORs) of LSM change in CGI scores did not show meaningful differences between groups (CGI-Improvement [patient]: OR [95% CI] 1.2 [0.80-1.73]; CGI-Improvement [physician]: 0.8 [0.47-1.36]; CGI-Severity [physician]: 1.0 [0.71-1.54]). CONCLUSIONS No significant differences were observed in change from baseline to week 72 between natalizumab Q6W and Q4W groups for all exploratory clinical or PRO-related endpoints assessed. For the EQ-5D-5 L, a higher proportion of Q6W than Q4W patients demonstrated worsening.
Collapse
Affiliation(s)
- Lana Zhovtis Ryerson
- Hackensack Meridian Medical Group - Neurology, Jersey Shore University Medical Center, Neptune City, NJ, United States of America.
| | - John F Foley
- Rocky Mountain MS Clinic, Salt Lake City, UT, United States of America
| | - Gilles Defer
- Department of Neurology, Centre Hospitalier Universitaire de Caen, Caen, France
| | - Jeffrey A Cohen
- Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States of America
| | - Douglas L Arnold
- Montréal Neurological Institute, McGill University, Montréal, QC, Canada; NeuroRx Research, Montréal, QC, Canada
| | - Helmut Butzkueven
- Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia
| | - Gary Cutter
- University of Alabama at Birmingham, School of Public Health, Birmingham, AL, United States of America
| | - Gavin Giovannoni
- Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK; Queen Mary University of London, London, UK
| | - Joep Killestein
- Department of Neurology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands
| | - Heinz Wiendl
- Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany
| | - Susie Sinks
- Biogen, Cambridge, MA, United States of America
| | | | | | - Tyler Lasky
- Biogen, Cambridge, MA, United States of America
| |
Collapse
|
28
|
Smith KT, Hallberg DL, Funk MA, Foley JF, Osborne IS, Lopez B, Szuromi P, Alderton G, Kelly PN, Hurtley SM, Stern P, Grocholski B, Olingy C. In Science Journals. Science 2023; 379:345-346. [PMID: 36701455 DOI: 10.1126/science.adg8140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Highlights from the Science family of journals.
Collapse
|
29
|
Foley JF. A check on the immunological synapse. Sci Signal 2023; 16:eadg6157. [PMID: 36649376 DOI: 10.1126/scisignal.adg6157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Blocking Nogo receptor 1 on natural killer cells enhances cell killing by stabilizing contact with target cells.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
30
|
Foley JF. CMTM4 makes IL-17 signaling more complex. Sci Signal 2022; 15:eadf9180. [DOI: 10.1126/scisignal.adf9180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
A transmembrane protein promotes the plasma membrane localization and signaling mediated by an IL-17 receptor subunit.
Collapse
|
31
|
Lopez B, Jiang D, Szuromi P, Ray LB, Foley JF, Papoutsakis ET, Williams I, Lavine MS, Scanlon ST, Vignieri S, Norton M, Hodges K, Hines PJ, Alderton G. In Science Journals. Science 2022. [DOI: 10.1126/science.adf8750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Highlights from the
Science
family of journals
Collapse
|
32
|
Gagné MR, Stern P, Vignieri S, Jiang D, Yeston J, Grocholski B, Malo CS, Foley JF, Kelly PN, Ray LB, Erkes DA, Morrison T. In Science Journals. Science 2022. [DOI: 10.1126/science.adf4743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Highlights from the
Science
family of journals
Collapse
|
33
|
Foley JF. Modulation by macrocyclic peptides. Sci Signal 2022; 15:eadf4115. [PMID: 36282909 DOI: 10.1126/scisignal.adf4115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Cell-permeable, macrocyclic peptides antagonize either the active or the inactive states of Gαs to fine-tune signaling.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
34
|
Abstract
By acquiring telomeres from antigen-presenting cells, some T cells are protected from senescence.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
35
|
Abstract
S-nitrosylation of the β2-adrenergic receptor induces its desensitization and internalization.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA
| |
Collapse
|
36
|
Lopez B, Vinson V, Suleymanov Y, Osborne IS, Lavine MS, Foley JF, Aldenderfer M, Jiang D, Hines PJ, Yeston J, Vignieri S, Grocholski B, Erkes DA, Norton M. In Science Journals. Science 2022. [PMID: 35951679 DOI: 10.1126/science.ade3192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Highlights from the Science family of journals.
Collapse
|
37
|
Foley JF. Taking the STING out of aging? Sci Signal 2022; 15:eadd7524. [DOI: 10.1126/scisignal.add7524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
By preventing STING activation, the transcriptional coactivators YAP/TAZ suppress cellular senescence.
Collapse
|
38
|
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N, Dwyer C, Buzzard K, Spies J, Parratt J, van Pesch V, Willekens B, Perrotta G, Bartholomé E, Grand'Maison F, Jacques F, Giacomini P, Vosoughi R, Girard JM, de Seze J, Lebrun Frenay C, Ruet A, Laplaud DA, Reifschneider G, Wagner B, Rauer S, Pul R, Seipelt M, Berthele A, Klotz L, Kallmann BA, Paul F, Achiron A, Lus G, Centonze D, Patti F, Grimaldi L, Hupperts R, Frequin S, Fermont J, Madueno SE, Alonso Torres AM, Costa-Frossard França L, Meca-Lallana JE, Ruiz LB, Pearson O, Rog D, Evangelou N, Ismail A, Lathi E, Fox E, Leist T, Sloane J, Wu G, Khatri B, Steingo B, Thrower B, Gudesblatt M, Calkwood J, Bandari D, Scagnelli J, Laganke C, Robertson D, Kipp L, Belkin M, Cohan S, Goldstick L, Courtney A, Vargas W, Sylvester A, Srinivasan J, Kannan M, Picone M, English J, Napoli S, Balabanov R, Zaydan I, Nicholas J, Kaplan J, Lublin F, Riser E, Miller T, Alvarez E, Wray S, Gross J, Pawate S, Hersh C, McCarthy L, Crayton H, Graves J. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol 2022; 21:608-619. [PMID: 35483387 DOI: 10.1016/s1474-4422(22)00143-0] [Citation(s) in RCA: 43] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 02/28/2022] [Accepted: 03/31/2022] [Indexed: 01/11/2023]
Abstract
BACKGROUND Treatment with natalizumab once every 4 weeks is approved for patients with relapsing-remitting multiple sclerosis, but is associated with a risk of progressive multifocal leukoencephalopathy. Switching to extended-interval dosing is associated with lower progressive multifocal leukoencephalopathy risk, but the efficacy of this approach is unclear. We aimed to assess the safety and efficacy of natalizumab once every 6 weeks compared with once every 4 weeks in patients with relapsing-remitting multiple sclerosis. METHODS We did a randomised, controlled, open-label, phase 3b trial (NOVA) at 89 multiple sclerosis centres across 11 countries in the Americas, Europe, and Western Pacific. Included participants were aged 18-60 years with relapsing-remitting multiple sclerosis and had been treated with intravenous natalizumab 300 mg once every 4 weeks with no relapses for at least 12 months before randomisation, with no missed doses in the previous 3 months. Participants were randomly assigned (1:1), using a randomisation sequence generated by the study funder and contract personnel with interactive response technology, to switch to natalizumab once every 6 weeks or continue with once every 4 weeks. The centralised MRI reader, independent neurology evaluation committee, site examining neurologists, site backup examining neurologists, and site examining technicians were masked to study group assignments. The primary endpoint was the number of new or newly enlarging T2 hyperintense lesions at week 72, assessed in all participants who received at least one dose of assigned treatment and had at least one postbaseline MRI, relapse, or neurological examination or efficacy assessment. Missing primary endpoint data were handled under prespecified primary and secondary estimands: the primary estimand included all data, regardless of whether participants remained on the assigned treatment; the secondary estimand classed all data obtained after treatment discontinuation or study withdrawal as missing. Safety was assessed in all participants who received at least one dose of study treatment. Study enrolment is closed and an open-label extension study is ongoing. This study is registered with EudraCT, 2018-002145-11, and ClinicalTrials.gov, NCT03689972. FINDINGS Between Dec 26, 2018, and Aug 30, 2019, 605 patients were assessed for eligibility and 499 were enrolled and assigned to receive natalizumab once every 6 weeks (n=251) or once every 4 weeks (n=248). After prespecified adjustments for missing data, mean numbers of new or newly enlarging T2 hyperintense lesions at week 72 were 0·20 (95% CI 0·07-0·63) in the once every 6 weeks group and 0·05 (0·01-0·22) in the once every 4 weeks group (mean lesion ratio 4·24 [95% CI 0·86-20·85]; p=0·076) under the primary estimand, and 0·31 (95% CI 0·12-0·82) and 0·06 (0·01-0·31; mean lesion ratio 4·93 [95% CI 1·05-23·20]; p=0·044) under the secondary estimand. Two participants in the once every 6 weeks group with extreme new or newly enlarging T2 hyperintense lesion numbers (≥25) contributed most of the excess lesions. Adverse events occurred in 194 (78%) of 250 participants in the once every 6 weeks group and 190 (77%) of 247 in the once every 4 weeks group, and serious adverse events occurred in 17 (7%) and 17 (7%), respectively. No deaths were reported. There was one case of asymptomatic progressive multifocal leukoencephalopathy (without clinical signs) in the once every 6 weeks group, and no cases in the once every 4 weeks group; 6 months after diagnosis, the participant was without increased disability and remained classified as asymptomatic. INTERPRETATION We found a numerical difference in the mean number of new or newly enlarging T2 hyperintense lesions at week 72 between the once every 6 weeks and once every 4 weeks groups, which reached significance under the secondary estimand, but interpretation of statistical differences (or absence thereof) is limited because disease activity in the once every 4 weeks group was lower than expected. The safety profiles of natalizumab once every 6 weeks and once every 4 weeks were similar. Although this trial was not powered to assess differences in risk of progressive multifocal leukoencephalopathy, the occurrence of the (asymptomatic) case underscores the importance of monitoring and risk factor consideration in all patients receiving natalizumab. FUNDING Biogen.
Collapse
Affiliation(s)
- John F Foley
- Rocky Mountain MS Clinic, Salt Lake City, UT, USA.
| | - Gilles Defer
- Department of Neurology, Centre Hospitalier Universitaire de Caen, Caen, France
| | | | - Jeffrey A Cohen
- Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Douglas L Arnold
- Montreal Neurological Institute, McGill University, Montréal, QC, Canada; NeuroRx Research, Montréal, QC, Canada
| | - Helmut Butzkueven
- Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia
| | - Gary Cutter
- University of Alabama at Birmingham, School of Public Health, Birmingham, AL, USA
| | - Gavin Giovannoni
- Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK; Queen Mary University of London, London, UK
| | - Joep Killestein
- Department of Neurology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands
| | - Heinz Wiendl
- Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Foley JF. Editorial expression of concern. Sci Signal 2022; 15:eadd4322. [PMID: 35727863 DOI: 10.1126/scisignal.add4322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
40
|
Foley JF. Editorial expression of concern. Sci Signal 2022; 15:eadd4323. [PMID: 35727862 DOI: 10.1126/scisignal.add4323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
41
|
Hines PJ, Lopez B, Ash C, Yeston J, Ray LB, Smith OM, Suleymanov Y, Osborne IS, Foley JF, Erkes DA. In Science Journals. Science 2022; 376:1179-1181. [PMID: 35679402 DOI: 10.1126/science.add3236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
42
|
Abstract
Both agonist binding and phosphorylation of the receptor C-tail are required for a GPCR to recruit and activate β-arrestins.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
43
|
Sugden AM, Funk MA, Malo CS, Szuromi P, Lavine MS, Okamoto R, Ash C, Ray LB, Yeston J, Osborne IS, Smith HJ, Zahn LM, Grocholski B, Foley JF, Williams I, Naeem S, Alderton G, Lopez B, Stern P. In Science Journals. Science 2022; 376:591-593. [PMID: 35536911 DOI: 10.1126/science.abq7834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Highlights from the Science family of journals.
Collapse
|
44
|
Foley JF. Shining a light on rhodopsin signaling. Sci Signal 2022; 15:eabq5583. [PMID: 35439024 DOI: 10.1126/scisignal.abq5583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Monitoring rhodopsin signaling in real time reveals the role of native lipids in modulating GPCR interactions.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
45
|
Aldenderfer M, Lavine MS, Grocholski B, Yeston J, Purnell BA, Stern P, Hallberg DL, Smith HJ, Sugden AM, Scanlon ST, Ray LB, Szuromi P, Foley JF, Williams I. In Science Journals. Science 2022; 376:258-260. [PMID: 35420941 DOI: 10.1126/science.abq4270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Highlights from the Science family of journals.
Collapse
|
46
|
Abstract
Obesity reversibly suppresses the antitumor activity of CD8+ T cells in mice and humans.
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
47
|
Grocholski B, Hurtley SM, Hodges K, Olingy C, Osborne IS, Stern P, Smith HJ, Jiang D, Ray LB, Funk MA, Szuromi P, Foley JF, Hallberg DL, Ash C. In Science Journals. Science 2022; 375:1140-1142. [PMID: 35271313 DOI: 10.1126/science.adb1879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Highlights from the Science family of journals.
Collapse
|
48
|
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- John F Foley
- Science Signaling, AAAS, Washington, DC 20005, USA.
| |
Collapse
|
49
|
Vignieri S, Hurtley SM, Szuromi P, Morel PA, Ash C, Hines PJ, Foley JF, Vinson V, Ray LB, Suleymanov Y, Nusinovich Y, Jiang D, Stajic J, Olingy C, Maroso M, Alderton G. In Science Journals. Science 2022; 375:278-280. [PMID: 35050644 DOI: 10.1126/science.ada0100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
[Figure: see text].
Collapse
|
50
|
Jiang D, Szuromi P, Foley JF, Vinson V, Yeston J, Kelly PN, Charneski CA, Alderton G, Scanlon ST, Vignieri S, Hines PJ, Osborne IS, Funk MA, Isles HM. In Science Journals. Science 2021; 374:1572-1574. [PMID: 34941403 DOI: 10.1126/science.acz9859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
[Figure: see text].
Collapse
|